ALLO vs DVA · rev $22.0K vs P/E 14, rev $12.82B
Allogene Therapeutics Inc (ALLO) versus DaVita HealthCare Partners Inc (DVA) — a side-by-side from cached financials, not a winner call.
Allogene Therapeutics Inc (ALLO) is a biotechnology company listed on US.
DaVita HealthCare Partners Inc (DVA) is a medical care facilities company listed on US.
Latest reported ALLO revenue for 2024-12-31 was $22.0K. Net income was -$257.6M. Revenue was down 76.8% from 2023-12-31 to 2024-12-31. ALLO currently screens at market cap $258.1M.
Latest reported DVA revenue for 2024-12-31 was $12.82B. Net income was $1.25B. Revenue was up 5.6% from 2023-12-31 to 2024-12-31. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
ALLO currently screens at market cap $258.1M. DVA currently screens at market cap $10.77B and trailing P/E 14.1.
Not investment advice. Open the ALLO and DVA stock pages for the full models.
Not investment advice.